Edgar Filing: ENDOCYTE INC - Form 4

ENDOCYTE INC

Form 4												
February 10, FORM	ГЛ	D STATES						NGE (COMMISSION		PPROVAL	
Check thi if no long subject to	ser STATE	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									Expires:January 31 2001Estimated average burden hours per response0.3	
Section 1 Form 4 of Form 5 obligation may cont <i>See</i> Instru 1(b).	r Filed p ^{ns} Section 1									response		
(Print or Type F	Responses)											
1. Name and Address of Reporting Person <u>*</u> Nguyen Binh			2. Issuer Name and Ticker or Trading Symbol ENDOCYTE INC [ECYT]					g	5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) 3000 KENT AVENUE, SUITE A1-100			3. Date of Earliest Transaction (Month/Day/Year) 02/06/2014					(Check all applicable) <u></u> Director <u></u> 10% Owner <u></u> Officer (give title <u></u> Other (specify below) <u>below</u>) VP of Medical Affairs				
	(Street)		4. If Amer Filed(Mon			e Original			6. Individual or Jo Applicable Line) _X_ Form filed by 0	One Reporting Pe	erson	
WEST LAF	AYETTE, IN 4	47906							Form filed by M Person	More than One Ro	eporting	
(City)	(State)	(Zip)	Table	e I - Nor	ı-De	erivative S	ecuri	ties Ac	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye	ar) Executionary	emed on Date, if /Day/Year)	Code (Instr.	8)	4. Securi nAcquired Disposed (Instr. 3, Amount	(A) o of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/06/2014			А		7,500 (1)	А	\$0	10,200	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ENDOCYTE INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 11.11	02/06/2014		А	45,000	(2)	02/06/2024	Common Stock	45,000

Reporting Owners

Reporting Owner Name / Address				
1 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Director	10% Owner	Officer	Other
Nguyen Binh 3000 KENT AVENUE, SUITE A1-100 WEST LAFAYETTE, IN 47906			VP of Medical Affairs	
Signatures				

Signatures

/s/ Michael A. Sherman, Attorney-in-fact for Binh Nguyen (power of attorney previously filed)					
**Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 6, 2015, in the form of one share of common stock for each restricted stock unit.
- (2) Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 6, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S